Search results | lundbeck

Reports

Partnering Agreements with Lundbeck

This report provides all the information you require to better understand Lundbeck and its partnering interests and activities over the past seven years.

Insights

Lundbeck: M&A activity 2005-2013

Lundbeck, a Denmark based big pharma company, has announced 4 M&A deals since 2005, with the lead deals being the acquisitions of Ovation Pharmaceuticals and Lifehealth.

Lundbeck: Partnering activity 2005-2013

Since 2005, Lundbeck, an international pharmaceutical company, announced over 50 partnering / licensing deals.

Lundbeck: Bravely battling brain diseases

Top 50 Pharma company Lundbeck is researching, developing and marketing medications for the treatment of brain diseases. 

Lundbeck: Company Profile

Lundbeck, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Lundbeck in search of potential pharma partners to develop Alzheimer’s treatment

H. Lundbeck A/S (LUN), the Nordic region’s second-largest drugmaker, failed to win recommendation from the European Union’s drug regulator for a treatment for Alzheimer’s disease, and is now seeking pharma partners to help develop the treatment

ImaginAb in pharma partnering with big pharma Lundbeck for neuro research

H. Lundbeck, a top 50 pharma company has entered in a pharma partnering pact with ImaginAB to develop biologics for treatment of nervous system ailments.

Is Lundbeck looking for Alzheimer’s pharma partners?

H. Lundbeck A/S (LUN), the Nordic region’s second-largest drugmaker, is in talks with several potential pharma partners to help develop a treatment for Alzheimer’s disease, Chief Executive Officer Ulf Wiinberg said.

Lundbeck and Otsuka ink blockbuster CNS deal

In one of the largest partnering deals of the year, Lundbeck and Otsuka have entered into a long-term agreement for the development and commercialization of up to five innovative psychiatric and neuroscience products worldwide

Genmab: Partnering activity 2009-2014

Genmab, a top big biotech company, headquartered in Denmark is one of the leaders today in the human antibody therapeutics market for cancer treatment.

Industry analysis in drug delivery partnering activity

Industry analysis reveals that over 2000 drug delivery partnering deals have been announced between January 2009 and April 2014, showing that drug delivery partnering is in good health, with numerous big pharma and big biotech companies actively partnering delivery technologies to support development of targeted therapeutics

Events

Sorry, your search returned no results.


Deals

Chelsea Therapeutics has entered into m&a with Lundbeck

Lundbeck and Chelsea Therapeutics International have entered into a definitive m&a agreement under which Lundbeck will acquire Chelsea.

Lundbeck and Lieber enter into biotech partnering for psychiatric disorders

Lundbeck is entering into a psychiatric disorders  with the Lieber Institute, which has the world’s largest collection of human brains from patients with psychiatric disorders.

Lundbeck and Otsuka form a pharma alliance for Selincro

Lundbeck has expanded its pharma alliance with Otsuka Pharmaceutical Co to include development and commercialisation of the alcohol dependence drug Selincro in Japan.

Proximagen biotech partnering with Lundbeck for protein kinase inhibitors

Proximagen Limited has entered into a preclinical biotech partnering agreement with Lundbeck, a big pharma company, to further its research program related to protein kinase inhibitors

Lundbeck and Otsuka are biopharma partners again for Alzheimer’s treatment

Lundbeck and Otsuka , both amongst the top 50 big biotech companies, announced a license and development biopharma partners agreement

Otsuka and Lundbeck enter pharma partnering pact for Ablify

Otsuka Pharmaceutical and H. Lundbeck, both being  big pharma companies, outlined co-promotion plans and summarized the overall progress in their pharma partnering at a session in Japan with representatives from domestic and international media organizations

Lundbeck & Recordati announce pharma partnering

Recordati announces successful pharma partnering alliance, concluding the acquisition of all rights concerning a portfolio of products indicated for the treatment of rare and other diseases and marketed mainly in the United States of America, from Lundbeck, a big pharma company.

Lundbeck in search of potential pharma partners to develop Alzheimer’s treatment

H. Lundbeck A/S (LUN), the Nordic region’s second-largest drugmaker, failed to win recommendation from the European Union’s drug regulator for a treatment for Alzheimer’s disease, and is now seeking pharma partners to help develop the treatment

ImaginAb in pharma partnering with big pharma Lundbeck for neuro research

H. Lundbeck, a top 50 pharma company has entered in a pharma partnering pact with ImaginAB to develop biologics for treatment of nervous system ailments.

Is Lundbeck looking for Alzheimer’s pharma partners?

H. Lundbeck A/S (LUN), the Nordic region’s second-largest drugmaker, is in talks with several potential pharma partners to help develop a treatment for Alzheimer’s disease, Chief Executive Officer Ulf Wiinberg said.

cpbannerad300x150new3gif
biovariabanner300x150gif
anglonordiccupart300x150jpg
RSS Feed Linked In Twitter

Latest Tweets

cpbannerad300x150new1gif
biovariabanner300x150gif
biowales-300x150-enjpg